47results about "CD44" patented technology

Pharmaceutical compositions and methods for treating cancer using CD44 antagonists are disclosed. In certain aspects, these pharmaceutical compositions and methods include treating a mammal having a cancer, such as glioma, colon cancer, breast cancer, prostate cancer, ovarian cancer, lung cancer, renal cell carcinoma, gastric cancer, esophageal cancer, head cancer, neck cancer, pancreatic cancer, or melanoma, with a CD44 fusion protein. These CD44 fusion proteins include CD44-Fc fusions and can be used to detect hyaluronan.

The invention discloses a new human endometrial cancer tumor marker through immune mice from human endometrial cancer oncoprotein. The marker is named GAB31, and is abnormally glycosylated CD44. The marker is characterized in that CD44 contains a saccharide structure Galb1-3(Neu5Aca2-6)GlcNAcb1-4Galb1-4Glcb of epitope; in addition, a monoclonal antibody of the antigen is specifically recognized through screening, an antibody capable of specifically recognizing the antigen is obtained, and it is found through immunomagnetic bead experiments for clinical samples that the EM2D9-MB positive detection rate of a detecting method that the antibody recognizes the antigen GAB31 is obviously higher than that of a conventional cast-off cell microscopic examination method.

The present invention is related to an antibiotic inducible / repressible genetic construct for controlling transcription of a gene of interest in a cell, and methods for its use. The genetic construct provides a plasmid vector comprising a polynucleotide molecule, two tetO sequences, and a single CMV promoter, wherein the polynucleotide molecule further comprises a fluorescent protein gene and an MCS upstream of the fluorescent protein gene, wherein a gene of interest encoding a protein of interest is cloned into the MCS so that a fusion protein comprising the protein of interest and the fluorescent protein may be produced, the polynucleotide molecule being operably linked to two tetO sequences and the single CMV promoter, and wherein the two tetO sequences are incorporated into the single CMV promoter.

The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of cancer and angiogenesis related diseases using cyclic peptides.

Provided are alternative splicing constructs and methods for their use. In particular, CD44 based alternative splicing constructs are provided that include CD44 exon 5. These alternative splicing constructs are useful in high-throughput assays for testing the effects of compounds on splicing and for achieving targeted cell death.

The present invention is based upon the identification of genes which are differentially expressed in hypertrophic cardiac tissue as compared to normal cardiac tissue. Accordingly, the present invention provides nucleotide sequences of genes selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9 and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. The invention also provides therapeutic methods and pharmaceutical compositions which are based on the promotion or inhibition of the function of the differentially expressed genes. The invention further provides methods of diagnosis, prognosis and screening for a disposition for diseases or disorders associated with cardiac hypertrophy. Methods for screening for modulators of the protein products of the differentially expressed genes in cardiac hypertrophy tissue are additionally provided.

The present invention relates to a protein which binds to the domain encoded by exon 9 of human CD44 (CD44ex9), to fusion proteins and conjugates of said protein and especially to nanoparticles conjugated to said protein. The invention further relates to a method of production for the protein and the respective conjugated nanoparticles and the use of the protein of the invention for treatment and diagnosis of cancer diseases.

The invention provides epitope polypeptide CD44-P2 based on a prostatic cancer stem cell marker CD44 and an application of the epitope polypeptide CD44-P2 and relates to the technical field of biological medicine engineering. According to the epitope polypeptide CD44-P2 based on the prostatic cancer stem cell marker CD44 and the application of the epitope polypeptide CD44-P2, the epitope polypeptide based on the prostatic cancer stem cell surface marker CD44 is designed and synthesized by a bioinformatics means, can sacrificially activate cytotoxic T lymphocytes, has good killing effects, canbe used for developing therapeutic peptide vaccines targeting prostatic cancer stem cells, a new technical scheme is provided for precise immunotherapy of malignant prostatic cancer, prostatic cancerstem cells can be specifically targeted, and relapse of prostatic cancer is reduced fundamentally.

The invention provides antigen epitope peptide CD44-P1 based on a prostatic cancer stem cell marker CD44 and application thereof, and relates to the technical field of biomedicine engineering. The antigen epitope peptide based on the prostatic cancer stem cell marker CD44 is designed and synthesized through bioinformatics means, specifically activates cytotoxicity T lymphocyte, has an excellent kill effect, can be applied to the development of prostatic cancer stem cell targeted therapeutic peptide vaccine, provides a novel technical scheme for the precise immunological therapy of malignant prostatic cancer, and can further specifically target prostatic cancer stem cell to reduce the recurrence of prostatic cancer.

A method of treating a neurodegenerative disorder is disclosed. The method comprises administering to the subject a therapeutically effective amount of an isolated peptide comprising at least 3 amino acids of a CD44V10 amino acid sequence no more than 20 amino acids of said CD44V10 amino acid sequence and comprising a neuroprotective activity.

The invention relates to a fusion protein comprising a polypeptide of interest, a transmembrane domain and an HIV gag polypeptide, or their functionally equivalent variants. The invention also relates to the polynucleotides, vectors, host cells and virus-like particles expressing or presenting said fusion proteins and to the pharmaceutical, immunogenic or vaccines composition containing said fusion proteins, polynucleotides, vectors, host cells and virus-like particles and their use in human and veterinary medicine.

The present invention relates to a protein which binds to the domain encoded by exon 9 of human CD44 (CD44ex9), to fusion proteins and conjugates of said protein and especially to nanoparticles conjugated to said protein. The invention further relates to a method of production for the protein and the respective conjugated nanoparticles and the use of the protein of the invention for treatment and diagnosis of cancer diseases.

The present invention relates to a protein which binds to the domain encoded by exon 9 of human CD44 (CD44ex9), to fusion proteins and conjugates of said protein and especially to nanoparticles conjugated to said protein. The invention further relates to a method of production for the protein and the respective conjugated nanoparticles and the use of the protein of the invention for treatment and diagnosis of cancer diseases.

Nanoparticles comprising a nucleic acid molecule encoding human ubiquitin-like protein 5 (UBL5) or human UBL5 protein are provided. Methods of treating a disease, disorder or condition characterized by mitochondrial stress are provided. Expression vectors, nucleic acid molecules, peptides, pharmaceutical compositions and methods of identifying a gene for use in gene therapy, targeting an agent to a CD44 expressing cell and producing a therapeutic nanoparticle are also provided.

The invention described herein provides antibodies or antigen-binding fragment thereof specific for an epitope within the variant exon v6 or v9 of the CD44 gene (CD44v6 or CD44v9), antibody-drug-conjugate (ADC) thereof, and other derivative comprising the antibodies or antigen-binding fragment thereof. The invention also provides nucleic acid molecules encoding the same, and methods of making the same. The invention further provides pharmaceutical compositions comprising the same, and the use of the same in treating diseases or in the manufacture of a medicament for the treatment of the diseases, such as cancer.

The present invention relates to methods for modulating efflux of drugs based on binding to a protein region of CD44 in part comprising the amino acid sequence specified in the provisional application referenced above, and incorporated in its entirety by reference herein (“PROV”). In some aspects, the present invention relates to methods for treatment of cancer by preventing the cellular efflux of therapeutic drugs; for example, preventing the cellular efflux of anti-cancer agents, for example a taxane, by contacting a CD44-modulating peptide, comprising the amino acid sequence specified in the provisional application referenced above, and incorporated in its entirety by reference herein (“PROV”).

The invention provides a method of producing human immature dental pulp stem cells (hIDPSCs) expressing CD44 and CD13 and lacking expression of CD146. The invention also provides compositions for use in the treatment of a neurological disease or condition selected from the group consisting of Parkinson's disease (PD), multiple sclerosis, amyotrophic lateral sclerosis (ALS), stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease, Huntington's disease (HD), autism, schizophrenia, stroke, ischemia, a motor disorder, and a convulsive disorder.

The invention relates to a fusion protein comprising a polypeptide of interest, a transmembrane domain and an HIV gag polypeptide, or their functionally equivalent variants. The invention also relates to the polynucleotides, vectors, host cells and virus-like particles expressing or presenting said fusion proteins and to the pharmaceutical, immunogenic or vaccines composition containing said fusion proteins, polynucleotides, vectors, host cells and virus-like particles and their use in human and veterinary medicine.

The present invention relates to LCK-binding coreceptor chimeric antigen receptors (CoCARs), combinations of coreceptor chimeric antigen receptors and CARs, nucleic acid constructs encoding such CoCARs, recombinant cells engineered to express such CoCARs, and pharmaceutical compositions comprising the same. Preferably, the present invention further provides its use in the treatment of diseases characterized by the expression of tumor-associated antigens.

The invention provides a method of producing human immature dental pulp stem cells (hIDPSCs) expressing CD44 and CD13 and lacking expression of CD146. The invention also provides compositions for use in the treatment of a neurological disease or condition selected from the group consisting of Parkinson's disease (PD), multiple sclerosis, amyotrophic lateral sclerosis (ALS), stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease, Huntington's disease (HD), autism, schizophrenia, stroke, ischemia, a motor disorder, and a convulsive disorder.

The invention provides epitope polypeptide CD44-P2 based on a prostatic cancer stem cell marker CD44 and an application of the epitope polypeptide CD44-P2 and relates to the technical field of biological medicine engineering. According to the epitope polypeptide CD44-P2 based on the prostatic cancer stem cell marker CD44 and the application of the epitope polypeptide CD44-P2, the epitope polypeptide based on the prostatic cancer stem cell surface marker CD44 is designed and synthesized by a bioinformatics means, can sacrificially activate cytotoxic T lymphocytes, has good killing effects, canbe used for developing therapeutic peptide vaccines targeting prostatic cancer stem cells, a new technical scheme is provided for precise immunotherapy of malignant prostatic cancer, prostatic cancerstem cells can be specifically targeted, and relapse of prostatic cancer is reduced fundamentally.

The present disclosure features methods, cells or cell lines, and compositions for increasing the amount of products, e.g., proteins, produced by a cell or cell line by reducing the level of a non-essential endogenous protein.

Embodiments of the present disclosure relate to compositions and methods of use related to certain immortalized cells, including cardiac muscle stem cells, obtained from pediatric or neonatal individuals. In certain embodiments, the immortalized cells, or conditioned medium derived from the cells, or a partial or entire secretome thereof, are provided to an individual in need thereof in an effective amount, either alone or in combination with cardiac muscle stem cells.

The present invention relates to a peptide bound to CD44v6 and uses for inhibiting cancer metastasis using the same, and the peptide of the present invention specifically binds to CD44v6 and inhibits it, thereby inhibiting cancer cell migration and metastasis. The peptides of the present invention selected two peptides (v6Pep-1 and v6Pep-2) that bind well to cells with high expression of human CD44v6 protein using phage peptide display technology and it was confirmed that it interferes with the binding between c-Met and CD44v6 to inhibit cancer cell migration. The peptide of the present invention is relatively stable in serum and shows a high potential as an anticancer treatment agent that suppresses metastasis due to the progression and migration of cancer in the future.

Methods and compositions are provided for the treatment and diagnosis of diseases related to hyperglycemic conditions, including diabetes, insulin resistance, and the like. Genetic polymorphisms are shown to be associated with disease susceptibility, and their detection is used in the diagnosis of a predisposition to these conditions. The corresponding proteins are useful as targets for therapeutic intervention.

The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of pancreatic cancer.

The present disclosure features methods, cells or cell lines, and compositions for increasing the amount of products, e.g., proteins, produced by a cell or cell line by reducing the level of a non-essential endogenous protein.

The present invention relates to a bFGF mesenchymal stem cell exosome and its preparation method and application. The bFGF mesenchymal stem cell exosome is secreted by mesenchymal stem cells and can express bFGF fusion protein on the mesenchymal stem cell membrane of exosomes. In the present invention, for the first time, bFGF is expressed on the membrane of mesenchymal stem cells and mesenchymal stem cell exosomes in the form of fusion protein, which can express a large amount of bFGF protein, and can enhance the specific targeting of mesenchymal stem cell exosomes , Significantly improves the effect of wound repair and reduces the formation of scars. The present invention provides a new safe and efficient drug or medical preparation or medical aesthetic product for promoting tissue repair.

The present invention provides compositions and methods for treating cardiac medical conditions such as heart failure caused by damaged myocardial tissue. [Solution] Embodiments of the present disclosure relate to compositions and methods of use relating to specific immortalized cells, including cardiomyocytes, obtained from pediatric or neonatal individuals. In specific embodiments, immortalized cells, or cell-derived conditioning media, or a partial or whole secretome thereof, are provided to individuals requiring it in an effective amount, either alone or in combination with cardiomyocytes.